TROG 07.04 - TROG Cancer Research

By w.paterson
23 June, 2021
0 Comments

A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

The purpose of this study is to assess the safety and feasibility of combining radiotherapy and carboplatin (a chemotherapy drug) with a new drug called cetuximab in patients with locally advanced head and neck cancer

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Final Accrual

Trial Chairperson

Assoc Prof June Corry, Peter MacCallum Cancer Centre, VIC
Prof Danny Rischin, Peter MacCallum Cancer Centre, VIC

Clinical Trial Registration

Registration Link

David, Jasmine and Susan Goode, re Kokoda Challenge to support TROG Cancer Research

27 May, 2025

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work

LATEST NEWS: 27 MAY 2025 TROG members and staff

A Phase I/II trial of Cetuximab, Carboplatin and Radiotherapy for patients with locally advanced Head and Neck Squamous Cell Carcinoma.

TROG 08.01 – PROFIT

TROG 07.03 – RadioHUM

Related Post

Intrepid trekkers to take on Kokoda Challenge for TROG

Clinical Trials Day celebrations help spread the work about TROG’s work